Exelixis (LTS:0IJO) Beginning Cash Position : $258 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Exelixis Beginning Cash Position?

Exelixis's Beginning Cash Position for the quarter that ended in Dec. 2024 was $258 Mil.

Exelixis's quarterly Beginning Cash Position declined from Jun. 2024 ($260 Mil) to Sep. 2024 ($198 Mil) but then increased from Sep. 2024 ($198 Mil) to Dec. 2024 ($258 Mil).

Exelixis's annual Beginning Cash Position declined from Dec. 2022 ($664 Mil) to Dec. 2023 ($503 Mil) and declined from Dec. 2023 ($503 Mil) to Dec. 2024 ($263 Mil).

Exelixis Beginning Cash Position Historical Data

The historical data trend for Exelixis's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Beginning Cash Position Chart

Exelixis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

268.14

320.77

663.89

502.68

262.99

Exelixis Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Beginning Cash Position	Get a 7-Day Free Trial															396.86	262.99	259.56	198.46	258.35

Exelixis Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Exelixis Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Exelixis's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

EXEL:USA EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Headlines

No Headlines